olivLaw · US equity research
Transcat, Inc. TRNS
Instruments For Meas & Testing of Electricity & Elec Signals · SIC 3825 · Vertical: Instruments For Meas & Testing of Electricity & Elec Signals (SIC 3825)
Transcat provides accredited calibration, maintenance and compliance services, and distributes and rents test and measurement instruments, mainly for regulated industries such as life sciences, aerospace and defense. In the first quarter of fiscal 2027 the company reported revenue of 92.9 million USD, with Service organic growth of 12.8%.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, Transcat, Inc. (TRNS) stock was 108.13 USD (+20.79% on the day), with market capitalisation 1.0 bn USD, P/E 226.7 on diluted EPS of 0.48 USD over the last 12 months, beta 0.95, 52-week range 52.06–108.13 USD. Latest reported quarter (Q2 2027): revenue of 97.1 m USD (+18.0% YoY), net income of 2.4 m USD (+90.1% YoY), diluted EPS 0.25 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 75.4
- overbought (≥ 70)
- Bollinger (20, 2)
- 74.61 – 97.87
- above the upper band · %B 1.44 · band width 27.0%
- SMA 50 / 200
- 86.54 / 82.02
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 2.10 / 0.19
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +19.4% | −1.1% | +20.5 pp | — |
| 3 months | +15.3% | −0.5% | +15.8 pp | — |
| 6 months | +43.9% | +4.4% | +39.5 pp | — |
| Year to date | +90.6% | +12.3% | +78.3 pp | — |
| 1 year | +73.4% | +13.5% | +59.9 pp | +47.7% |
| 3 years | +24.8% | +76.4% | −51.6 pp | +51.5% |
| 5 years | +20.0% | +63.7% | −43.7 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2027 · 26 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 | Q1 '27 | Q2 '27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 66.8 m | 77.1 m | 76.4 m | 82.3 m | 83.9 m | 89.3 m | 92.9 m | 97.1 m |
| Cost of revenue | 47.1 m | 51.2 m | 50.6 m | 55.5 m | 58.6 m | 58.9 m | 62.2 m | 64.5 m |
| Gross profit | 19.7 m | 25.9 m | 25.8 m | 26.8 m | 25.3 m | 30.5 m | 30.7 m | 32.6 m |
| Operating income | 2.1 m | 6.9 m | 5.3 m | 3.5 m | 88.0 k | 4.3 m | 3.7 m | 5.0 m |
| Depreciation & amortisation | 4.4 m ≈ | 5.6 m | 5.6 m | 6.5 m ≈ | 7.1 m ≈ | 7.0 m | 7.0 m | 6.8 m ≈ |
| Interest expense | 199.0 k | 471.0 k | 451.0 k | 1.3 m | 1.5 m | 1.4 m | 1.5 m | 1.6 m |
| Pre-tax income | 3.1 m | 6.3 m | 4.6 m | 2.0 m | -1.4 m | 2.8 m | 2.2 m | 3.2 m |
| Income tax | 772.0 k | 1.8 m | 1.3 m | 760.0 k | -338.0 k | 887.0 k | 854.0 k | 767.0 k |
| Net income | 2.4 m | 4.5 m | 3.3 m | 1.3 m | -1.1 m | 1.9 m | 1.3 m | 2.4 m |
| Diluted EPS | 0.25 | 0.48 ≈ | 0.35 | 0.14 | -0.12 | 0.21 ≈ | 0.14 | 0.25 |
| Operating cash flow | 12.6 m ≈ | 10.6 m | 3.6 m | 12.9 m ≈ | 12.1 m ≈ | 6.2 m | 8.8 m | 10.1 m ≈ |
| Capex | 2.9 m ≈ | 2.7 m | 4.6 m | 4.4 m ≈ | 2.7 m ≈ | 3.6 m | 4.0 m | 4.1 m ≈ |
| Share repurchases | 182.0 k ≈ | 357.0 k | 0 | 110.0 k ≈ | -13.0 k ≈ | 372.0 k | 1.9 m | — |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 98 percentile of its own 40-quarter history (min 16.4, median 45.3, max 251.3; quarters with earnings only).
Fiscal years
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 160.9 m | 173.1 m | 173.3 m | 205.0 m | 230.6 m | 259.5 m | 278.4 m | 331.9 m |
| Revenue YoY | +3.7% | +7.6% | +0.1% | +18.2% | +12.5% | +12.5% | +7.3% | +19.2% |
| Net income | 7.1 m | 8.1 m | 7.8 m | 11.4 m | 10.7 m | 13.6 m | 14.5 m | 5.4 m |
| Net income YoY | +20.7% | +12.9% | −3.4% | +46.1% | −6.1% | +27.7% | +6.4% | −63.0% |
| Diluted EPS | 0.95 | 1.08 | 1.03 | 1.50 | 1.40 | 1.63 | 1.57 | 0.57 |
| Diluted EPS YoY | +17.3% | +13.7% | −4.6% | +45.6% | −6.7% | +16.4% | −3.7% | −63.7% |
| net % | 4.4% | 4.7% | 4.5% | 5.6% | 4.6% | 5.3% | 5.2% | 1.6% |
| Free cash flow | 5.6 m | 5.0 m | 17.0 m | 7.5 m | 7.5 m | 19.3 m | 25.8 m | 19.6 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2026 · 28 Mar 2026
- Cash
- 4.9 m USD
- Financial debt
- 99.9 m USD
- Net debt
- 94.9 m USD
- Equity
- 300.6 m USD
- Total assets
- 480.5 m USD
- Debt / equity
- 0.33x
- Current ratio
- 2.33x
- ROE
- 1.8%
- ROA
- 1.2%
- FCF margin
- 5.9%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 173.3 m | 205.0 m | 230.6 m | 259.5 m | 278.4 m | 331.9 m | SEC (XBRL)· 27 May 2026verified |
| Cost of revenue | 127.2 m | 146.5 m | 162.2 m | 175.7 m | 189.0 m | 223.6 m | SEC (XBRL)· 27 May 2026verified |
| Gross profit | 46.1 m | 58.4 m | 68.4 m | 83.8 m | 89.5 m | 108.3 m | SEC (XBRL)· 27 May 2026verified |
| Operating income | 11.1 m | 14.1 m | 16.2 m | 19.8 m | 17.9 m | 13.3 m | SEC (XBRL)· 27 May 2026verified |
| Depreciation & amortisation | 7.6 m | 9.6 m | 11.0 m | 13.5 m | 18.6 m | 26.2 m | SEC (XBRL)· 27 May 2026verified |
| EBITDA | 18.7 m ≈ | 23.7 m ≈ | 27.2 m ≈ | 33.3 m ≈ | 36.4 m ≈ | 39.4 m ≈ | SEC (XBRL)· 27 May 2026derived |
| Interest expense | — | 810.0 k | 2.4 m | 1.8 m | 798.0 k | 4.6 m | SEC (XBRL)· 27 May 2026verified |
| Pre-tax income | 10.0 m | 13.2 m | 13.5 m | 18.4 m | 18.3 m | 8.0 m | SEC (XBRL)· 27 May 2026verified |
| Income tax | 2.2 m | 1.8 m | 2.8 m | 4.8 m | 3.8 m | 2.6 m | SEC (XBRL)· 27 May 2026verified |
| Net income | 7.8 m | 11.4 m | 10.7 m | 13.6 m | 14.5 m | 5.4 m | SEC (XBRL)· 27 May 2026verified |
| Diluted EPS | 1.03 | 1.50 | 1.40 | 1.63 | 1.57 | 0.57 | SEC (XBRL)· 27 May 2026verified |
| Weighted average diluted shares | 7.5 m | 7.6 m | 7.6 m | 8.4 m | 9.3 m | 9.4 m | SEC (XBRL)· 27 May 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 560.0 k | 1.4 m | 1.5 m | 19.6 m | 1.5 m | 4.9 m | SEC (XBRL)· 27 May 2026verified |
| Receivables | 34.0 m | 39.7 m | 44.7 m | 47.8 m | 55.9 m | 65.2 m | SEC (XBRL)· 27 May 2026verified |
| Inventories | 11.6 m | 12.7 m | 16.9 m | 17.4 m | 14.5 m | 13.7 m | SEC (XBRL)· 27 May 2026verified |
| Current assets | 48.9 m | 59.7 m | 67.6 m | 105.2 m | 78.0 m | 92.5 m | SEC (XBRL)· 27 May 2026verified |
| Property, plant & equipment, net | 22.2 m | 26.4 m | 29.1 m | 38.9 m | 50.0 m | 57.8 m | SEC (XBRL)· 27 May 2026verified |
| Goodwill | 43.3 m | 65.1 m | 69.4 m | 105.6 m | 176.9 m | 218.2 m | SEC (XBRL)· 27 May 2026verified |
| Intangibles (excl. goodwill) | 7.5 m | 14.7 m | 13.8 m | 20.0 m | 54.8 m | 77.7 m | SEC (XBRL)· 27 May 2026verified |
| Total assets | 132.1 m | 177.8 m | 195.7 m | 287.6 m | 385.2 m | 480.5 m | SEC (XBRL)· 27 May 2026verified |
| Accounts payable | 12.3 m | 14.2 m | 15.9 m | 11.5 m | 16.8 m | 17.9 m | SEC (XBRL)· 27 May 2026verified |
| Short-term debt | 2.1 m | 2.2 m | 2.2 m | 2.3 m | 1.8 m | 0 | SEC (XBRL)· 27 May 2026verified |
| Long-term debt | 17.5 m | 46.3 m | 46.9 m | 1.8 m | 30.9 m | 99.9 m | SEC (XBRL)· 27 May 2026verified |
| Current liabilities | 25.1 m | 27.7 m | 28.3 m | 33.5 m | 34.0 m | 39.6 m | SEC (XBRL)· 27 May 2026verified |
| Total liabilities | 57.0 m | 91.6 m | 96.1 m | 62.4 m | 98.4 m | 179.9 m | SEC (XBRL)· 27 May 2026verified |
| Equity | 75.1 m † | 86.2 m † | 99.6 m † | 225.2 m † | 286.9 m † | 300.6 m † | SEC (XBRL)· 27 May 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 23.6 m | 17.6 m | 17.0 m | 32.6 m | 39.0 m | 34.9 m | SEC (XBRL)· 27 May 2026verified |
| Capex | 6.6 m | 10.2 m | 9.4 m | 13.3 m | 13.2 m | 15.3 m | SEC (XBRL)· 27 May 2026verified |
| Free cash flow | 17.0 m ≈ | 7.5 m ≈ | 7.5 m ≈ | 19.3 m ≈ | 25.8 m ≈ | 19.6 m ≈ | SEC (XBRL)· 27 May 2026derived |
| Investing cash flow | -10.2 m | -39.9 m | -18.5 m | -41.7 m | -84.0 m | -97.8 m | SEC (XBRL)· 27 May 2026verified |
| Financing cash flow | -12.7 m | 23.7 m | 876.0 k | 27.4 m | 26.9 m | 66.5 m | SEC (XBRL)· 27 May 2026verified |
| Share repurchases | 3.0 m | 6.7 m | 447.0 k | 4.9 m | 3.6 m | 469.0 k | SEC (XBRL)· 27 May 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 35 / 100
A scoring methodology on indicators and valuation, not investment advice.
score < 40
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 1.0 bn USD
Key indicators
Coverage and freshness
Score by group
- Balance sheet23
- Valuation26
- Quality55
- Growth50
- Returns3
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 12.27 – 85.06 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)36.70 – 65.07 (Mid 47.51)WACC 8.8% · starting FCFF 27.0 m USD · terminal value share of EV 75%The WACC × g sensitivity gives the method's bounds; these are not probabilities.Reverse DCF: no growth between −30% and +40% justifies the price
- Peers: EV/EBITDA66.02 – 85.06 (Mid 82.60)5 companies used · median multiple 21.6x · quartiles 17.8x – 22.2xALNT, INTT, ITRI, TER, VLTO
- Peers: P/E12.27 – 14.63 (Mid 13.78)4 companies used · median multiple 28.9x · quartiles 25.7x – 30.7xALNT, ITRI, TER, VLTO
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Unattractive profile · Score 35/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 2.2% | 33 (vs peers) | 11% |
| Net margin · Quality | 1.3% | 44 (vs peers) | 7% |
| FCF conversion · Quality | 500.5% | 100 (on a fixed band) | 7% |
| Revenue CAGR 3Y · Growth | 12.9% | 100 (on a fixed band) | 9% |
| EPS CAGR 3Y · Growth | -25.9% | 0 (on a fixed band) | 9% |
| Net debt / EBITDA · Balance sheet | 2.7x | 0 (vs peers) | 11% |
| Interest coverage · Balance sheet | 2.2x | 11 (on a fixed band) | 7% |
| Current ratio · Balance sheet | 2.6x | 100 (on a fixed band) | 4% |
| P/E (TTM) · Valuation | 226.7x | 33 (vs peers) | 11% |
| EV/EBITDA · Valuation | 27.5x | 17 (vs peers) | 11% |
| FCF yield · Valuation | 2.3% | 28 (on a fixed band) | 9% |
| Shareholder yield (distributions) · Returns | 0.2% | 3 (on a fixed band) | 7% |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet23/100 · 3/3 factors with a value
- Growth50/100 · 2/2 factors with a value
- Quality55/100 · 3/3 factors with a value
- Returns· partial3/100 · 1/2 factors with a value
- Valuation26/100 · 3/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
TRANSCAT, INC. (TRNS). Latest full fiscal year: 2026; data up to 2026-09-26.
Figures computed from the financial statements: revenue 331.9 m USD in 2026; YoY growth 19.2%; net margin 1.3%; ROE 1.5%; net debt/EBITDA 2.7x.
The estimated value range is 36.70–65.07 USD per share (median of 3 methods, agreement: low); assumptions are illustrative. Against the central value of 47.51 USD, the price of 108.13 USD leaves a potential of -56.1% (value / price − 1) and a margin of safety of -127.6% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 35/100, methodological classification: unattractive profile (score, margin of safety and method agreement together; not a judgement of the right price). Groups assessed only in part: returns. Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- FCF conversion: 500.5%
- Revenue CAGR 3Y: 12.9%
- Current ratio: 2.6x
What contradicts it
- EPS CAGR 3Y: -25.9%
- Net debt / EBITDA: 2.7x
- Interest coverage: 2.2x
- EV/EBITDA: 27.5x
- FCF yield: 2.3%
- Shareholder yield (distributions): 0.2%
- The price is above the estimated value range
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): Payout ratio (FCF).
Versus the vertical median
Instruments For Meas & Testing of Electricity & Elec Signals (SIC 3825) · same industry (4-digit SIC) · compared with 9 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| TERTeradyne, Inc. | 39.2 bn | 28.8 | 42.9% | 27.5% | +13.1% | +38% / +172% |
| VLTOVeralto Corporation | 28.5 bn | 28.9 | 33.0% | 17.3% | +6.0% | +16% / +51% |
| ITRIItron, Inc. | 4.5 bn | 16.4 | 16.5% | 12.1% | −3.0% | +3% / +51% |
| COHUCohu, Inc. | 2.1 bn | — | -2.8% | -4.0% | +12.7% | +81% / +39% |
| AEHRAehr Test Systems | 2.0 bn | — | -4.2% | -14.3% | −15.2% | +165% / +165% |
| ALNTAllient Inc | 1.4 bn | 35.8 | 12.1% | 6.2% | +4.6% | +48% / +205% |
| TRNSTranscat, Inc. | 1.0 bn | 226.7 | 1.5% | 1.3% | +19.2% | +73% / +25% |
| FEIMFrequency Electronics, Inc. | 693.5 m | 243.8 | 3.0% | 3.7% | −9.4% | +115% / +523% |
| INTTinTest Corporation | 175.9 m | 335.2 | 0.6% | 0.5% | −12.9% | +74% / +7% |
| DAIOData I | 25.2 m | — | -61.2% | -50.1% | −1.2% | −16% / −16% |
1- and 3-year price returns: for TRNS from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 70.91 Total return -34% · Per year -34% | 124.90 Total return 16% · Per year 16% | 187.50 Total return 73% · Per year 73% |
| 3 years | 80.95 Total return -25% · Per year -9% | 159.23 Total return 47% · Per year 14% | 260.67 Total return 141% · Per year 34% |
| 5 years | 92.40 Total return -15% · Per year -3% | 202.99 Total return 88% · Per year 13% | 362.39 Total return 235% · Per year 27% |
- Exit P/E± 39.81
- Net margin± 27.87
- Annual revenue growth± 21.17
- Annual dilution± 2.34
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 04 Aug 2026; since then the company filed 8-K (03 Nov 2026 · results), 10-Q (03 Nov 2026).
In brief
Transcat provides accredited calibration, maintenance and compliance services, and distributes and rents test and measurement instruments, mainly for regulated industries such as life sciences, aerospace and defense. In the first quarter of fiscal 2027 the company reported revenue of 92.9 million USD, with Service organic growth of 12.8% 2.
SWOT
Strengths
Weaknesses
Opportunities
Risks
- Acquisition integrationhigh
If integration of acquisitions does not succeed, results could fall short of expectations and goodwill could be impaired 1.
- Goodwill impairmentmedium
Goodwill and intangible assets are tested annually; a deterioration in assumptions could lead to impairment with direct effect on results 1.
- Concentration in regulated industriesmedium
If life sciences or energy industries slow, demand for services could fall at the same time 1.
- Trade and tariffsmedium
Changes in trade policy and tariffs could raise costs and reduce margins, especially in Distribution 1.
- Debt and financing costslow
Debt has increased after acquisitions, and interest costs could weigh on net income and cash flow 23.
Investment thesis
What would need to be true (bull case)
- Organic growth in Service remained in double digits, and recurring revenue from regulated customers provides a stable base 23.
- If Service margins keep expanding, profitability could recover gradually as new contracts mature 3.
- Growth in adjusted EBITDA suggests operating cash generation has advanced faster than net income 3.
What would break the thesis
- Net income and operating margin fell in the first quarter, due to amortization and integration costs 2.
- Distribution gross margin declined significantly, which could point to price pressure from competitors 3.
- Long-term debt has risen, and if acquisitions underperform the financial burden could become harder to manage 3.
What to watch
- Service organic growth against guidance of high single digitsfiscal 2027
- Service gross margin trend as new contracts matureQ2 2027
- Integration of SCM and performance of Central American operationsfiscal 2027
- Debt level and operating free cash flownext quarterly report
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 04 Aug 2026; since then the company filed 8-K (03 Nov 2026 · results), 10-Q (03 Nov 2026).
The business
Transcat, Inc. is a provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, CMMS and pipette services, headquartered in Rochester, New York 1. It runs two segments: Service, covering calibration and laboratory services, and Distribution, which sells and rents national and proprietary brand instruments 1. In fiscal 2026 total revenue was 331.9 million USD, of which 217.2 million USD came from Service and 114.7 million USD from Distribution 1.
The company aims for Service to be the main source of revenue and earnings growth, given higher gross margins and recurring revenue from regulated customers 1. Recent acquisitions, Essco, Martin, Becnel and SCM in April 2026, aimed at geographic and capability expansion 13. In Distribution, rentals and used equipment are used to diversify the customer base 1.
Customers are concentrated in life sciences, pharmaceuticals, medical devices, aerospace, defense, energy and utilities 1. No single customer or group accounted for 3% or more of revenue in fiscal 2026 or 2025 1.
Market context
The calibration market is fragmented, ranging from internationally accredited corporations to non-accredited providers, and demand is supported by regulation from the FDA and FAA 1. Distribution demand depends on customers' capital and discretionary spending and is more sensitive to the economic cycle 1.
The company says it is gaining share in calibration services through organic growth and acquisitions, and that demand in life sciences and aerospace remains strong 3. Central America is a new expansion market following the SCM acquisition 3.
Trends
- Acquisitions and integrationmixed
Recent acquisitions added geographic reach in Boston and Minnesota, but also raised amortization and integration costs 12.
- Instrument rentalstailwind
Rentals are described as a growth area supporting both Distribution and Service 13.
- Inflation and energy costsheadwind
Persistent inflation and rising energy prices could raise operating and labor costs and pressure margins 1.
- Regulated demand in life sciencestailwind
Regulation in pharmaceuticals and medical devices creates steady demand for accredited calibration, supporting recurring revenue 13.
Competitive position
In Service the company competes with regional providers, integrated facilities management firms and original equipment manufacturers that offer their own calibration services 1. In Distribution, competition comes from manufacturers selling direct, web-based distributors and larger rivals with greater financial resources 1.
The sources do not name specific competitors but describe categories: fragmented calibration providers, large distributors and web retailers 1. Some competitors have broader capabilities and stronger name recognition 1.
- Regional and local calibration providers
Local or regional service providers in Service, with varying levels of accreditation 1.
- Integrated facilities management companies
Compete in Service with whole-facility service packages 1.
- Original equipment manufacturers offering calibration
Some instrument makers offer their own calibration and compliance services 1.
- Web-based and large distributors
In Distribution, online and large distributors are gaining share and have wider customer bases 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Quarterly report03 Nov 2026
- Current report03 Nov 2026Results of operations · Financial statements and exhibits
- Current report10 Sept 2026Shareholder vote
- Quarterly report04 Aug 2026
- Current report04 Aug 2026Results of operations · Financial statements and exhibits
- Proxy statement23 Jul 2026
- Annual report27 May 2026
- Current report26 May 2026Results of operations · Financial statements and exhibits
- Current report19 May 2026Departure or appointment of officers
- Current report09 Mar 2026Material agreement · Departure or appointment of officers · Regulation FD disclosure · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2026-03-28 · SEC / Transcat, Inc. · 27 May 2026
- [2] Form 10-Q, quarter ended 2026-06-27 · SEC / Transcat, Inc. · 04 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Transcat, Inc. · 04 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.